Fulgent Genetics Inc.

# Signal Note: RTW Investments Initiates Position in Fulgent Genetics RTW's $18.5M entry into FLGT suggests conviction in the company's clinical-stage pipeline or near-term commercial catalysts, though the timing warrants scrutiny given FLGT's primary business remains molecular diagnostics and reproductive genetics testing rather than drug development. Key catalysts to monitor include any Phase 2/3 readouts for proprietary therapeutics, M&A activity, or margin expansion from higher-margin test volumes; absent specific pipeline clarity, this appears more consistent with Wong's value/operational improvement thesis than a breakthrough indication play.